cortistatin D | 882976-98-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: cortistatin D
• 英文别名: (1S,2R,5R,6S,12R,13R,14S,16R)-14-(dimethylamino)-5,12,13-trihydroxy-5-isoquinolin-7-yl-6-methyl-19-oxapentacyclo[14.2.1.01,9.02,6.011,16]nonadeca-8,10-dien-4-one
• CAS: 882976-98-9
• 化学式: C₃₀H₃₄N₂O₅
• 分子量: 502.6
• InChiKey: VSVYWUPPYDXESC-OMXDIREYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  37
• 可旋转键数：
  2
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  103
• 氢给体数：
  3
• 氢受体数：
  7

文献信息

• CORTISTATIN ANALOGUES AND SYNTHESES THEREOF
  申请人：Flyer Alec Nathanson

  公开号：US20110190323A1

  公开（公告）日：2011-08-04

  The present invention relates to analogs of cortistatin A, J, K, and L, having the general formula: I and salts thereof, wherein R 1 , R 2 , R 3 , R 4 , n, and m are as defined herein; processes for preparing such compounds and intermediates thereto; pharmaceutical compositions comprising such compounds; methods for treating a proliferative disease; methods for treating a disease associated with aberrant angiogenesis; methods for inhibiting angiogenesis; and processes for preparing cortistatin A, J, K, and L, and analogs thereof.
• CORTISTATIN ANALOGUES AND SYNTHESES THEROF
  申请人：President and Fellows of Harvard College

  公开号：US20150111921A1

  公开（公告）日：2015-04-23

  The present invention relates to analogs of cortistatin A, J, K, and L, having the general formula: I and salts thereof, wherein R 1 , R 2 , R 3 , R 4 , n, and m are as defined herein; processes for preparing such compounds and intermediates thereto; pharmaceutical compositions comprising such compounds; methods for treating a proliferative disease; methods for treating a disease associated with aberrant angiogenesis; methods for inhibiting angiogenesis; and processes for preparing cortistatin A, J, K, and L, and analogs thereof.
• US9127019B2
  申请人：——

  公开号：US9127019B2

  公开（公告）日：2015-09-08
• US9714255B2
  申请人：——

  公开号：US9714255B2

  公开（公告）日：2017-07-25
• [EN] TARGETED SELECTION OF PATIENTS FOR TREATMENT WITH CORTISTATIN DERIVATIVES<br/>[FR] SÉLECTION CIBLÉE DE PATIENTS POUR UN TRAITEMENT PAR DÉRIVÉS DE CORTISTATINE
  申请人：HARVARD COLLEGE

  公开号：WO2016182904A1

  公开（公告）日：2016-11-17

  A method for the targeted selection and treatment of patients with a tumor or cancer, comprising (i) determining whether the patient has a RUNX1 pathway impairment; and if so (ii) administering an effective amount of a cortistatin or its pharmaceutically acceptable salt or oxide, optionally in a pharmaceutically acceptable composition.